U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 [PDF 0.69 MB] and Volume 2 [PDF 1.28 MB] of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 131 - 140 of 925

Involuntary Commitment: Ethics at the Nexus of Mental Health Care and Homelessness

This Issue Brief will discuss some interpersonal practices and communication strategies that clinicians can incorporate to lessen the trauma involved in involuntary commitment, and look at some considerations for structural and systemic change.
Format
Report/Paper/Issue Brief
Audience
Communities
Policymakers and Payers
Medical Providers
Behavioral Health Providers
Source
National Health Care for the Homeless Council
Year
Resource Type
PDF
File Size
3.6 MB

LGBTQ+ Behavioral Health Equity Center of Excellence

This training provides behavioral health professionals with vital information regarding treatment for individuals in the LGBTQ+ community. The training highlights health disparities and unmet needs in the LGBTQ community and best practices for practitioners.
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
Web Page

MATE Act Training Requirements Questions & Answers

This web page provides frequently asked questions regarding the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Drug Enforcement Administration (DEA)
Year
Resource Type
Web Page

Medication-Assisted Treatment (MAT) for Opioid Use Disorder in Jails and Prisons: A Planning and Implementation Toolkit (2023 Revised)

This toolkit provides correctional administrators and health care providers recommendations and tools for implementing MAT in correctional settings and strategies for overcoming challenges.
Format
Toolkit
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF
File Size
4 MB

Medications for Substance Use Disorders (SAMHSA)

This is an overview of resources that provide information about how medications can be used to treat substance use disorders and prevent overdose, including Food and Drug Administration (FDA)-approved medications for the treatment of alcohol use disorders.

Format
Web Page
Audience
Behavioral Health Providers
Medical Providers
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
Web Page

Medications to Treat Opioid Use Disorder

This fact sheet includes basic descriptions of medications for opioid use disorders (MOUD) including naltrexone, buprenorphine, and methadone. It also addresses how MOUD can help those struggling with opioid use disorder, misunderstandings about MOUD, and additional considerations.
Format
Fact Sheet/Brochure
Audience
Patients
Families
Medical Providers
Other Team Members
Communities
Schools
Source
Partnership to End Addiction
Year
Resource Type
Web Page

mHealth Index & Navigation Database (MIND)

This webpage provides a library of mental health apps, including those related to substance use, and provides evaluations based on the American Psychiatric Association's App Evaluation Model.
Format
Digital Therapeutics
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Patients
Communities
Source
Division of Digital Psychiatry at the Beth Israel Deaconess Medical Center
Year
Resource Type
Web Page

Mitigating Risks from Human Xylazine Exposure

This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research.
Format
Webinar/Video
Audience
Behavioral Health Providers
Medical Providers
Other Team Members
Communities
Policymakers and Payers
States
Source
Regan-Udall Foundation for the FDA
Year
Resource Type
Web Page